Burgess, M. A., Crowley, J., Reinke, D. K., Riedel, R. F., George, S., Movva, S., … Tawbi, H.-H. (2015). SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Burgess, Melissa Amber, John Crowley, Denise K. Reinke, Richard F. Riedel, Suzanne George, Sujana Movva, Brian Andrew Van Tine, et al. “SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.

Burgess MA, Crowley J, Reinke DK, Riedel RF, George S, Movva S, et al. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.

Burgess, Melissa Amber, et al. “SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.

Burgess MA, Crowley J, Reinke DK, Riedel RF, George S, Movva S, Van Tine BA, Davis LE, Schuetze S, Hu J, Attia S, Priebat DA, Reed DR, D’Angelo SP, Okuno SH, Maki RG, Patel S, Baker LH, Tawbi HA-H. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.